Completing enrolment is normally a scheduling update. This one is worth reading because of the sentence BD put beside it: no products are currently approved for this. PREVENT is not testing a product against a competitor, it is testing whether an indication can be brought into existence. Prophylactic reinforcement means implanting material into the abdominal wall of a patient who does not have a hernia and may never get one, and there is at present no label, no code and no payer precedent for doing that. BD is spending 477 patients and five years to build all three.

• Resorbable is the enabling decision, not a product feature. Asking a surgeon to place a permanent synthetic implant into a well patient’s healthy abdominal wall is a proposition that has to survive chronic pain, infection risk, the possibility of explantation and a patient who was fine before the operation. A mesh that resorbs and leaves reinforced native tissue behind is the only version of that conversation a surgeon can comfortably have with someone who has no hernia. The material choice is what makes prophylaxis conceivable at all, which is why this trial runs on Phasix rather than on the permanent portfolio sitting next to it.
• Competitive frame: enrolment was the doubt, and that is precisely why it is worth announcing. Prevention trials in surgery fail at recruitment more often than at readout, because a surgeon must ask a patient to accept an extra implant for a problem they do not yet have, and many will not make that request. Completing 477 patients across 32 sites in two regulatory regions establishes that surgeons in both will randomise. That is the question which kills most prophylaxis programmes before they ever generate data, and BD has now answered it. Everything after this point is time rather than uncertainty.
• The number to demand is the high-risk definition, not the hernia rate. A 24-month primary means data around mid-2028 and a submission after that, so a label is a 2029 conversation at the earliest and the strategy language in this announcement is running about three years ahead of the evidence. When the readout lands, the enrolment criteria will matter more than the effect size, because they determine how narrow the eventual indication is and whether the economics can carry an additional implant into an operation that currently does not include one. A prevention claim only becomes a business once someone agrees to pay for an absence of events.